The US Food and Drug Administration (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection. The fast track pathway is designed to ...

The FDA has granted Fast Track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.

Sanofi’s Pasteur vaccines unit and Translate Bio have expanded a collaboration to develop mRNA-based vaccines across all infectious disease areas. The deal builds on an agreement signed in 2018 ...

Sanofi SNY announced that the FDA has granted a fast-track designation to its mRNA vaccine candidate for the prevention of chlamydia infection. The company plans to begin a phase I/II study soon ...

As part of the Fast Track designation, Sanofi is set to launch a Phase I/II trial to evaluate the immunogenicity and safety of its novel mRNA vaccine in preventing chlamydia. The FDA has granted Fast ...

Flu vaccines reduce the risk of GP presentation with influenza by 30-60 per cent and hospitalisation with influenza by 50-70 ...

Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of ...

Novavax's $500M Sanofi partnership with a potential $700M ... Health Secretary Kennedy's claim that single-antigen vaccines don't work for respiratory diseases caused Novavax stock to plummet ...

(RTTNews) - Sanofi (SNYNF, SNY) announced Wednesday that the US Food and Drug Administration has granted fast track designation to the company's mRNA vaccine candidate for the prevention of ...

Sanofi’s chlamydia vaccine candidate was designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis. The Food and Drug Administration (FDA ...